The effect of long-term iron treatment on plasma isoprostanes in anaemic wome

Completed

• Conditions: Anaemia; Iron deficiency anaemia; Haematological Disorders

• Registration Number: ISRCTN57167465
• Lead Sponsor: Kings College London (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-10-06
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 16

Inclusion Criteria

1. Females aged 18 to 50 years
2. Iron deficiency anaemia, defined as haemoglobin less than 12 g/dl, and mean corpuscular volume (MCV) less than 90 fl and serum ferritin less than 20 ug/l

Exclusion Criteria

1. Suffer from serious chronic illness
2. Body mass index above 30
3. Smoker
4. Taking prescription drugs including contraceptive medicines
5. Regularly take medicines containing aspirin or ibuprofen
6. Pregnant or breastfeeding or are planning to become pregnant in the next two months
7. Moderately/severely elevated cholesterol (more than 6.0 mmol/l), as these factors affect either iron absorption or plasma isoprostane concentration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma isoprostane concentration after daily iron treatment for 28 days.

Secondary Outcome Measures

Name	Time	Method
The secondary outcome is serum NTBI. In addition to measuring the primary outcome (plasma isoprostanes) before and once after once daily ferrous sulphate treatment for 28 days, we will also measure serum NTBI before and once after daily ferrous sulphate treatment for 28 days in all subjects.